Patients with the MS were more insulin resistant than control individuals as evidenced by the increased concentrations of glucose (P < 0.001) and insulin (P < 0.001), and the higher homeostatic model assessment (HOMA) and lower quantitative insulin sensitivity check index (QUICKI) (P < 0.001 for both). This evidence concerns the gene INS and myeloid sarcoma.